Vaccines the tugboat for prevention-based animal production

Nimmanapalli, Ramadevi; Gupta, Vikas

doi:10.1016/b978-0-12-816352-8.00020-5

Cited by 4 publications

(3 citation statements)

References 135 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In case of food-borne diseases, such as Salmonella enterica colonizing the gut of chickens, it is recommended that a multiple strategy, considering licensed killed and live vaccines, should be used [36]. Federally licensed autogenous vaccines can be used to tailor the vaccination strategy to further decrease prevalence and level of contamination of the carcasses at the processing plant [37,38]. As several types of salmonella can be present at different levels of the poultry production [39][40][41], it has been recommended to consider Salmonella enterica isolates/serovars found at processing plant monitoring as autogenous vaccine candidates [42].…”

Section: Vaccine Candidate(s) Selectionmentioning

confidence: 99%

Autogenous Vaccines in the Poultry Industry: A Field Perspective

Palomino-Tapia

2023

Poultry Farming - New Perspectives and Applications

View full text Add to dashboard Cite

Emergent economically important diseases affecting the poultry industry in the face of commercial vaccination programs in place might require custom-made vaccines to be controlled in the field. These custom-made vaccines (“autogenous”), albeit requiring less regulatory burden than fully licensed commercial vaccines, are restricted in their scope and field isolates and can only be used in particular areas/operations. This chapter summarizes field and research experience of the author with some viral and bacterial autogenous vaccine programs (e.g., Avian Reovirus, Fowl Adenovirus, Infectious Bursal Disease Virus, Salmonella enterica spp., Escherichia coli, Clostridium spp.), as well as commentaries on regulations, and adjuvant technologies used in the poultry industry.

show abstract

Section: Vaccine Candidate(s) Selectionmentioning

confidence: 99%

Autogenous Vaccines in the Poultry Industry: A Field Perspective

Palomino-Tapia

2023

Poultry Farming - New Perspectives and Applications

View full text Add to dashboard Cite

show abstract

“…It undergoes two endogenous phases (schizogony and gametogony) and is initiated by the sporozoite infection of the host cecum, leading to hemorrhagic lesions ( 6 ). To control avian coccidiosis, both vaccination and prophylactic anticoccidial drug administration (chemotherapy) are the widely used methods ( 7 , 8 ). However, the used vaccines, either attenuated or non-attenuated live oocysts, show a risk of reaction development in the vaccinated chickens with different degrees ( 9 ).…”

Section: Introductionmentioning

confidence: 99%

S-Methylcysteine Ameliorates the Intestinal Damage Induced by Eimeria tenella Infection via Targeting Oxidative Stress and Inflammatory Modulators

et al. 2022

View full text Add to dashboard Cite

Avian coccidiosis is one of the major parasitic diseases in the poultry industry. The infection is caused by Eimeria species, and its treatment relies mainly on the administration of anticoccidial drugs, which can result in drug resistance and side effects. The recent trends in avian coccidiosis treatment is directed to the development of a new therapy using herbal compounds. S-Methylcysteine (SMC) is considered one of the organosulfur compounds in garlic that showed promising activity in the treatment of different pathological conditions via a wide range of anti-inflammatory and antioxidant mechanisms. In this study, the anticoccidial activity of SMC was investigated in Eimeria tenella-infected chickens compared to diclazuril as a widely used anticoccidial drug. In this regard, 14-day-old broilers were divided into six groups (n = 18). The first group (G1) was the healthy control group, while the second group (G2) was the non-infected SMC group treated at a dose of 50 mg/kg b.w. (high dose). Moreover, the third group (G3) was the positive control group (infected and non-treated). The fourth group (G4) was the infected group treated with SMC of 25 mg/kg b.w. (low dose), while the fifth group (G5) was the infected group treated with SMC of 50 mg/kg b.w. (high dose). Conversely, the sixth group (G6) was the diclazuril-treated group. The anticoccidial effects of SMC and diclazuril were evaluated by counting oocysts and recording the body weight gain, feed conversion ratio, clinical signs, lesions, and mortality rate. Interestingly, SMC showed potent anticoccidial activity, which was exemplified by reduction of oocyst count. Furthermore, the biochemical, antioxidant, and anti-inflammatory parameters in the cecal tissues were restored toward their control levels in G4, G5, and G6. Histopathological observation of cecal tissues was consistent with the aforementioned results revealing the ameliorative effect of SMC against E. tenella infection. This study concluded novel findings in relation to the anticoccidial role of SMC as a plant-based compound against the E. tenella-induced coccidiosis in broiler chickens combined with its antioxidative and anti-inflammatory properties. Further studies for exploring the mechanistic pathways involved in this activity and the potential benefits from its use in association with conventional anticoccidial drugs are warranted.

show abstract

“…Pasteur and his team coined the idea of attenuation and defended its use with pasteurella multocida, responsible for diarrhea in chickens. Later, anthrax vaccine in sheep and rabies vaccine in animals and humans were developed using the attenuation approach [3]. The concept of inactivation of a pathogen without losing immunogenicity was devised at the end of the 19th century.…”

Section: Introductionmentioning

confidence: 99%

Nucleic Acid Vaccines for COVID-19: A Paradigm Shift in the Vaccine Development Arena

et al. 2021

View full text Add to dashboard Cite

Coronavirus disease, COVID-19, has touched every country globally except five countries (North Korea, Turkmenistan, Tonga, Tuvalu and Nauru). Vaccination is the most effective method to protect against infectious diseases. The objective is to ensure that everyone has access to a COVID-19 vaccine. The conventional vaccine development platforms are complex and time-consuming to obtain desired approved vaccine candidates through rigorous regulatory pathways. These safeguards guarantee that the optimized vaccine product is safe and efficacious for various demographic populations prior to it being approved for general use. Nucleic acid vaccines employ genetic material from a pathogen, such as a virus or bacteria, to induce an immune response against it. Based on the vaccination, the genetic material might be DNA or RNA; as such, it offers instructions for producing a specific pathogen protein that the immune system will perceive as foreign and mount an immune response. Nucleic acid vaccines for multiple antigens might be made in the same facility, lowering costs even more. Most traditional vaccine regimens do not allow for this. Herein, we demonstrate the recent understanding and advances in nucleic acid vaccines (DNA and mRNA based) against COVID-19, specifically those in human clinical trials.

show abstract

Vaccines the tugboat for prevention-based animal production

Cited by 4 publications

References 135 publications

Autogenous Vaccines in the Poultry Industry: A Field Perspective

Autogenous Vaccines in the Poultry Industry: A Field Perspective

S-Methylcysteine Ameliorates the Intestinal Damage Induced by Eimeria tenella Infection via Targeting Oxidative Stress and Inflammatory Modulators

Nucleic Acid Vaccines for COVID-19: A Paradigm Shift in the Vaccine Development Arena

Contact Info

Product

Resources

About